Evidence map›Paper›PMID 20864819›Full record

ArticleCell cycle (Georgetown, Tex.)2010

HIF1-alpha functions as a tumor promoter in cancer associated fibroblasts, and as a tumor suppressor in breast cancer cells: Autophagy drives compartment-specific oncogenesis.

Barbara Chiavarina, Diana Whitaker-Menezes, Gemma Migneco, Ubaldo E Martinez-Outschoorn, Stephanos Pavlides, Anthony Howell, Herbert B Tanowitz, Mathew C Casimiro, Chenguang Wang, Richard G Pestell and 4 more

Open access · hybridAbstract read
In one paragraph

Article in Cell cycle (Georgetown, Tex.), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 152 papers.

0numbers the graph read from it
0cells of the map it votes in
152citing papers in PubMed
8.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

152 citing papers in PubMed, 228 citations in OpenAlex.

  1. Review
  2. Review
  3. The fibroinflammatory response in cancer.Nature reviews. Cancer · 2025
    Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Cancer Metabolism under Limiting Oxygen Conditions.Cold Spring Harbor perspectives in medicine · 2024
    Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review

92 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 2 countries.

Barbara ChiavarinaDepartment of Stem Cell Biology & Regenerative Medicine, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA.
Diana Whitaker-Menezes
Gemma Migneco
Ubaldo E Martinez-Outschoorn
Stephanos Pavlides
Anthony Howell
Herbert B Tanowitz
Mathew C Casimiro
Chenguang Wang
Richard G Pestell
Philip Grieshaber
Jaime Caro
Federica Sotgia
Michael P Lisanti
Thomas Jefferson University · USPhiladelphia University · USSidney Kimmel Cancer Center · USAlbert Einstein College of Medicine · USManchester Academic Health Science Centre · GB

Funding

X-Ray Crystallography and Macromolecular CharacterizationP30CA056036 · NCI · THOMAS JEFFERSON UNIVERSITY · PI DANIEL P SILVER · 1995 to 2026
$94.8M
Initiation and Maintenance In Mammary TumorigenesisR01CA075503 · NCI · YESHIVA UNIVERSITY · PI PESTELL, RICHARD G · 1998 to 2011
$4.6M
CAV-1, Stat5a Signaling, and Estrogen-Dependent Breast CancerR01CA098779 · NCI · YESHIVA UNIVERSITY · PI FRANK, PHILIPPE G. · 2003 to 2012
$3.5M
SIGNALING AND CELL TRANSFORMATIONR01CA080250 · NCI · YESHIVA UNIVERSITY · PI LISANTI, MICHAEL P · 1999 to 2008
$3.4M
CYCLIN D1 FUNCTION IN PROSTATE CANCERR01CA086072 · NCI · YESHIVA UNIVERSITY · PI PESTELL, RICHARD G · 2001 to 2013
$3.3M
REGULATION OF CYCLIN D1 EXPRESSIONR01CA070896 · NCI · YESHIVA UNIVERSITY · PI PESTELL, RICHARD G · 2000 to 2010
$3.2M
Role of Caveolin in Scleroderma Tissue Fibrosis and VasculopathyR01AR055660 · NIAMS · THOMAS JEFFERSON UNIVERSITY · PI JIMENEZ, SERGIO A · 2008 to 2012
$1.7M
Cyclin D1 Regulation of Nuclear Receptor Function in Breast CancerR01CA107382 · NCI · THOMAS JEFFERSON UNIVERSITY · PI PESTELL, RICHARD G · 2004 to 2008
$1.6M
CAV-1 Epithelial-Stromal Interactions and Breast CancerR01CA120876 · NCI · THOMAS JEFFERSON UNIVERSITY · PI LISANTI, MICHAEL P · 2007 to 2011
$1.5M
NCI NIH HHS P30 CA056036NCI NIH HHS P30-CA-56036NCI NIH HHS R01 CA070896NCI NIH HHS R01 CA075503NCI NIH HHS R01 CA080250NCI NIH HHS R01-CA-080250NCI NIH HHS R01 CA086072NCI NIH HHS R01 CA098779NCI NIH HHS R01-CA-098779NCI NIH HHS R01 CA107382NCI NIH HHS R01-CA-107382NCI NIH HHS R01 CA120876NCI NIH HHS R01-CA-120876NCI NIH HHS R01-CA-70896NCI NIH HHS R01-CA-75503NCI NIH HHS R01-CA-86072NIAMS NIH HHS R01 AR055660NIAMS NIH HHS R01-AR-055660
6 · The paper itself

Abstract

Our recent studies have mechanistically implicated a loss of stromal Cav-1 expression and HIF1-alpha-activation in driving the cancer-associated fibroblast phenotype, through the paracrine production of nutrients via autophagy and aerobic glycolysis. However, it remains unknown if HIF1a-activation is sufficient to confer the cancer-associated fibroblast phenotype. To test this hypothesis directly, we stably-expressed activated HIF1a in fibroblasts and then examined their ability to promote tumor growth using a xenograft model employing human breast cancer cells (MDA-MB-231). Fibroblasts harboring activated HIF1a showed a dramatic reduction in Cav-1 levels and a shift towards aerobic glycolysis, as evidenced by a loss of mitochondrial activity, and an increase in lactate production. Activated HIF1a also induced BNIP3 and BNIP3L expression, markers for the autophagic destruction of mitochondria. Most importantly, fibroblasts expressing activated HIF1a increased tumor mass by ∼2-fold and tumor volume by ∼3-fold, without a significant increase in tumor angiogenesis. In this context, HIF1a also induced an increase in the lymph node metastasis of cancer cells. Similar results were obtained by driving NFκB activation in fibroblasts, another inducer of autophagy. Thus, activated HIF1a is sufficient to functionally confer the cancer-associated fibroblast phenotype. It is also known that HIF1a expression is required for the induction of autophagy in cancer cells. As such, we next directly expressed activated HIF1a in MDA-MB-231 cells and assessed its effect on tumor growth via xenograft analysis. Surprisingly, activated HIF1a in cancer cells dramatically suppressed tumor growth, resulting in a 2-fold reduction in tumor mass and a 3-fold reduction in tumor volume. We conclude that HIF1a activation in different cell types can either promote or repress tumorigenesis. Based on these studies, we suggest that autophagy in cancer-associated fibroblasts promotes tumor growth via the paracrine production of recycled nutrients, which can directly "feed" cancer cells. Conversely, autophagy in cancer cells represses tumor growth via their "self-digestion". Thus, we should consider that the activities of various known oncogenes and tumor-suppressors may be compartment and cell-type specific, and are not necessarily an intrinsic property of the molecule itself. As such, other "classic" oncogenes and tumor suppressors will have to be re-evaluated to determine their compartment specific effects on tumor growth and metastasis. Lastly, our results provide direct experimental support for the recently proposed "Autophagic Tumor Stroma Model of Cancer".

Indexed as

AutophagyAnimalsBreast NeoplasmsCaveolin 1Cell Line, TumorDisease ProgressionFemaleFibroblastsGlycolysisHumansHypoxia-Inducible Factor 1, alpha SubunitLactatesLymphatic MetastasisMembrane ProteinsMiceMitochondriaBNIP3L protein, humanBNIP3 protein, humanCaveolin 1Hypoxia-Inducible Factor 1, alpha SubunitLactatesMembrane ProteinsNF-kappa BProto-Oncogene ProteinsTumor Suppressor Proteins

Identifiers

PMID20864819
PMCPMC3047618
OpenAlexW2032128015

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.